Company Description
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease.
Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer.
The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.
Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells.
The company was incorporated in 2016 and is based in Boston, Massachusetts.
| Country | United States |
| IPO Date | Jul 8, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Thomas A. Fitzgerald M.B.A. |
Contact Details
Address: 6 Liberty Square Boston, Massachusetts United States | |
| Website | https://www.transcodetherapeutics.com |
Stock Details
| Ticker Symbol | RNAZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001829635 |
| CUSIP Number | 89357L105 |
| ISIN Number | US89357L3033 |
| Employer ID | 81-1065054 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas A. Fitzgerald M.B.A. | Interim Chief Executive Officer, Chief Financial Officer, President, Vice President of Administration & Director |
| Dr. Anna Moore Ph.D. | Co-Founder, Scientific Advisor & Member of Scientific Advisory Board |
| Dr. Daniel R. Vlock M.D. | Chief Medical Officer |
| Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. | Executive Chairman of the Board |
| Dr. Zdravka Medarova Ph.D. | Co-Founder & Chief Scientific Officer |
| Susan Duggan M.B.A., R.N. | Senior Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 30, 2024 | DEF 14A | Filing |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 19, 2024 | PRE 14A | Filing |
| Dec 12, 2024 | D | Filing |
| Dec 06, 2024 | S-1 | Filing |
| Dec 02, 2024 | 8-K | Current Report |
| Nov 29, 2024 | 8-K | Current Report |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | DEFA14A | Filing |